课题基金 / 基金详情

Developing GalR1/2 Agonists to Treat Nerve Gas Induced Seizure

Developing GalR1/2 Agonists to Treat Nerve Gas Induced Seizure
开发 GalR1/2 激动剂来治疗神经毒气引起的癫痫发作
批准号:
7696013
负责人:
TAMAS BARTFAI
金额:
$94.58万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-16 至 2011-05-30
关键词:
AcetylcholineAdverse effectsAffectAffinityAgonistAlkaloidsAlkylationAnticonvulsantsAntidotesAntiepileptogenicAtropineAttenuatedBelladonnaBlood - brain barrier anatomyBrainBrain InjuriesCardiovascular systemCellsCessation of lifeCharacteristicsChemicalsChemistryCholinergic AgentsClassClinicalClonazepamConvulsionsDataDevelopmentDigit structureDrug InteractionsDrug KineticsElectroconvulsive ShockEnzymesEpilepsyEventExposure toG-Protein-Coupled ReceptorsGalaninGalnonGas PoisoningGlutamatesGoalsHilarHippocampus (Brain)Human ResourcesIn VitroIon ChannelLeadLeftLevetiracetamLigandsLiliumMeasuresMediatingMilitary PersonnelModelingMolecular WeightMuscarinic Acetylcholine ReceptorNeuraxisNeuropeptide ReceptorOrganophosphatesOximesPathologyPenetrationPersonal CommunicationPharmaceutical ChemistryPharmaceutical PreparationsPhasePhysostigminePilocarpineProphylactic treatmentPublishingRecruitment ActivityReportingRespiratory FailureRodentSarinScreening procedureSeizuresSeriesSignal TransductionSiteSodiumSomanStandards of Weights and MeasuresStatus EpilepticusStructureStructure-Activity RelationshipSubwaySynapsesTestingTokyoToxicologyTreatment ProtocolsVigabatrinbasecheminformaticscholinergicesterasefelbamategalactose receptorgalanin receptorgalmicgamma-Aminobutyric Acidhigh throughput screeningimprovedin vivomolecular modelingnerve gasneuroprotectionneurotransmissionnovelpeptidomimeticspre-clinicalpreclinical studypresynapticreceptorresearch facilityresearch studyrespiratorytiagabinetransmission process

项目摘要

项目成果

TAMAS BARTFAI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Nerve gases, such as sarin and soman, are classified as weapons of mass destruction. Exposure to organophosphate nerve gases (OP-NG), on the battle field or through terrorist actions like the Tokyo subway incident, leads to convulsions, respiratory failure, and ultimately death. Current prophylaxis and therapy regimen are not effective for OP-NG induced seizures, which usually progress rapidly into status epilepticus, causing profound brain damage. In this proposal, we aim at the development of potent novel anticonvulsants for the treatment of OP-NG induced seizures. This will be achieved by targeting two G-protein coupled receptors (GPCR) in the central nervous system, Gal-R1 and Gal-R2. Both Gal-R1 and Gal-R2 are receptors for the neuropeptide galanin and are expressed at high levels in the hippocampus of the rodent brain. Preclinical studies have shown that signaling through these two galanin receptor subtypes mediates potent anticonvulsant actions. In order to develop potent Gal-R1 and Gal-R2 agonists we embark on three independent approaches: The target profile is as follows: double digit nanomolar affinity for Gal-R1 and or Gal-R2 receptors, agonist activity, at least 50 fold selectivity over other GPCRs and ion channels that are involved in the control of seizure, rapid onset of action, anticonvulsant activity when applied after OP-NG exposure, and no cardiovascular or respiratory side effect and low drug interaction potential. The chemical starting points of this project are excellent as we have already obtained several Gal-R1 and Gal-R2 ligands and our in vivo experiments demonstrate the anticonvulsant potency of these compounds in several seizure models, when the compounds are applied systemically. Successful development of Gal-R1 and Gal-R2 agonists will not only provide a powerful countermeasure against the terrorist threat but also could bring a new treatment mechanism for seizure/epilepsy. Seizure is a fatal consequence following nerve gas exposure. Counter-terrorist measures proposed here include the identification and development of a novel and potent anticonvulsant agent to protect military personal and civilians from the effect of OP-NG exposure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
  • 批准号:
    7899875
  • 项目类别:
  • 资助金额:
    $94.66万
  • 财政年份:
    2008
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
  • 批准号:
    7541156
  • 项目类别:
  • 资助金额:
    $94.58万
  • 财政年份:
    2008
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
Developing GalR 1/2 Agonists to Treat Nerve Gas Induced Seizure
  • 批准号:
    7687924
  • 项目类别:
  • 资助金额:
    $94.47万
  • 财政年份:
    2008
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
Galanin and GalR2 Receptors in Antidepressant Treatments
  • 批准号:
    7682825
  • 项目类别:
  • 资助金额:
    $39.1万
  • 财政年份:
    2006
  • 负责人:
    TAMAS BARTFAI
  • 依托单位:
海外基金